Anti-Mouse CD90 (Thy-1) (Clone M5/49.4.1) – Purified in vivo PLATINUM™ Functional Grade
Anti-Mouse CD90 (Thy-1) (Clone M5/49.4.1) – Purified in vivo PLATINUM™ Functional Grade
Product No.: C645
- -
- -
Clone M5/49.4.1 Target Thy1 (CD90) Formats AvailableView All Product Type Hybridoma Monoclonal Antibody Alternate Names Thy-1 membrane glycoprotein, CD90 Isotype Rat IgG2a Applications Depletion , FA , IP |
- -
- -
Antibody DetailsProduct DetailsHost Species Rat Recommended Dilution Buffer Immunogen Secondary mixed lymphocyte culture consisting of C57BL/6 mouse anti-irradiated BN rat lymphoma Product Concentration ≥ 5.0 mg/ml Endotoxin Level <0.5 EU/mg as determined by the LAL method Purity ≥98% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. State of Matter Liquid Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Pathogen Testing To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM<sup>TM</sup> antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles. Regulatory Status Research Use Only Country of Origin USA Shipping 2 – 8° C Wet Ice Additional Applications Reported In Literature ? Depletion, FA, IP Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity M5/49.4.1 activity is directed against mouse Thy1 (CD90). Background Thy1 is a highly conserved, GPI-linked member of the immunoglobulin superfamily that is
important in the immune and nervous systems1 and involved in T-cell activation and cell-cell
interactions2. The effects of Thy1 are context-dependent1. Thy1 is heavily N-glycosylated with a
carbohydrate content of up to 40% of its molecular mass, and its moiety composition varies
between tissues as well as between cells of the same lineage in different stages of differentiation.
Additionally, Thy1 is found in both membrane-bound and soluble forms, and, in mice, Thy1 is
encoded by two alleles, Thy1.1 and Thy1.2, which are distinguished by a single amino acid at
position 891. Thy1 deficiency does not compromise immunity2, but its presence or absence
modulates the phenotypes of certain cancers, fibrotic diseases, and neuronal injury1. Thy1.1 is an
alloantigen of the AKR/J and PL mouse strains, whereas Thy1.2 is expressed by most mouse
strains2,3. M5/49.4.1 was generated by immunizing (Lewis x BN) F1 rats with a secondary mixed lymphocyte culture consisting of C57BL/6 mouse anti-irradiated BN rat lymphoma4. Spleen cells were fused with NS-1 myeloma cells and hybridomas grown and assessed for binding to cytolytic T lymphocyte (CTL) surface molecules. Antigen Distribution CD90 is expressed in mice by thymocytes, peripheral T-cells, myoblasts,
epidermal cells, and keratinocytes. CD90 is considered a pan T cell marker of mice. Ligand/Receptor CD45 NCBI Gene Bank ID Research Area Immunology . Signal Transduction . Immunoglobulins References & Citations1 Bradley JE, Ramirez G, Hagood JS. Biofactors. 35(3):258-265. 2009. 2 Haeryfar SM, Hoskin DW. J Immunol. 173(6):3581-3588. 2004. 3 Rege TA, Hagood JS. FASEB J. 20(8):1045-1054. 2006. 4 Davignon D, Martz E, Reynolds T, et al. Proc Natl Acad Sci U S A. 78(7):4535-4539. 1981. 5 Weng X, Liao CM, Bagchi S, et al. Eur J Immunol. 44(12):3646-3657. 2014. Technical ProtocolsCertificate of Analysis |
Formats Available
